ReviewJournal of biomedicine & biotechnology2012
Heterologous expression of plant cell wall degrading enzymes for effective production of cellulosic biofuels.
Review in Journal of biomedicine & biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 48 citations in OpenAlex.
- Acidothermus cellulolyticus E1 endoglucanase expressed in planta undergoes extensive hydroxyproline-O-glycosylation and exhibits enhanced impact on biomass digestibility.Plant cell reports · 2024Article
- Zymomonas mobilis as an emerging biotechnological chassis for the production of industrially relevant compounds.Bioresources and bioprocessing · 2021Review
- Management of microbial enzymes for biofuels and biogas production by using metagenomic and genome editing approaches.3 Biotech · 2021Review
- Current Trends in Experimental and Computational Approaches to Combat Antimicrobial Resistance.Frontiers in genetics · 2020Review
- Plant Molecular Farming - Integration and Exploitation of Side Streams to Achieve Sustainable Biomanufacturing.Frontiers in plant science · 2018Review
- In planta expression of hyperthermophilic enzymes as a strategy for accelerated lignocellulosic digestion.Scientific reports · 2017Article
- Zymomonas mobilis as a model system for production of biofuels and biochemicals.Microbial biotechnology · 2016Review
- Polysaccharide degradation systems of the saprophytic bacterium Cellvibrio japonicus.World journal of microbiology & biotechnology · 2016Review
- Engineering a highly active thermophilic β-glucosidase to enhance its pH stability and saccharification performance.Biotechnology for biofuels · 2016Article
- Structural Insight of a Trimodular Halophilic Cellulase with a Family 46 Carbohydrate-Binding Module.PloS one · 2015Article
- Challenges and advances in the heterologous expression of cellulolytic enzymes: a review.Biotechnology for biofuels · 2014Article
- Advances in the genetic dissection of plant cell walls: tools and resources available in Miscanthus.Frontiers in plant science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major technical challenge in the cost-effective production of cellulosic biofuel is the need to lower the cost of plant cell wall degrading enzymes (PCDE), which is required for the production of sugars from biomass. Several competitive, low-cost technologies have been developed to produce PCDE in different host organisms such as Escherichia coli, Zymomonas mobilis, and plant. Selection of an ideal host organism is very important, because each host organism has its own unique features. Synthetic biology-aided tools enable heterologous expression of PCDE in recombinant E. coli or Z. mobilis and allow successful consolidated bioprocessing (CBP) in these microorganisms. In-planta expression provides an opportunity to simplify the process of enzyme production and plant biomass processing and leads to self-deconstruction of plant cell walls. Although the future of currently available technologies is difficult to predict, a complete and viable platform will most likely be available through the integration of the existing approaches with the development of breakthrough technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.